Marpai, Inc. (MRAI): M&A transaction — Marpai files Maestro Health financials; acquired co. net loss $29.3M in 2021

Marpai, Inc.

Maestro Health 2021 revenue $19.4M, net loss $29.3M; members' deficit $35.1M as of Dec 31, 2021.
Unaudited nine-month 2022 financial statements included; acquisition closed Nov 1, 2022.
Pro forma combined financials filed; Maestro Health reports going concern with AXA support through May 2023.
Marpai acquired Maestro Health via membership interest purchase; no deal value disclosed in this filing.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 1.0

Marpai, Inc. completed an acquisition involving Maestro Health, LLC for Membership Interest Purchase Agreement executed by and among the Company, X.L. America, Inc., Seaview Re Holdings Inc., and AXA S.A. (closed 2022-11-01).

Action: acquisition
Counterparty: Maestro Health, LLC
Consideration: Membership Interest Purchase Agreement executed by and among the Company, X.L. America, Inc., Seaview Re Holdings Inc., and AXA S.A.
Closing: 2022-11-01

Exact text from the filing

On November 1, 2022, Marpai, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) to report the Company’s consummation of Maestro Health, LLC (“Maestro Health”), a Delaware limited liability company, pursuant to the terms of the Membership Interest Purchase Agreement executed by and among the Company, X.L. America, Inc., a Delaware corporation, Seaview Re Holdings Inc., a Delaware corporation, and AXA S.A., a French société anonyme.

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Marpai, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.